New A-PRP Medical Device & Tissue Engineering Composition, Manufacturing Machines And Process

1 . A system for preparing a cell composition, comprising:

a tube adapted to centrifuge a blood to separate a platelet rich plasma, the tube having:

an anticoagulant;

a cell selector gel including a polymer, the cell selector gel adapted to separate the blood by forming a barrier between the platelet rich plasma and red blood cells when the tube is centrifuged for a length of time;

at least one hyaluronic acid selected from the following:

a hyaluronic acid of approximately 1000 KDa to approximately 2000 KDa;

a hyaluronic acid of approximately 4000 KDa or above 4000 KDa;

a hyaluronic acid of approximately 600 KDa or less than 600 KDa;

the at least one hyaluronic acid mixing with the platelet rich plasma to form the cell composition.

2 . The system of claim 1 , wherein the at least one hyaluronic acid is selected from the following:

a hyaluronic acid of approximately 1000 KDa to approximately 2000 KDa;

a hyaluronic acid of approximately 600 KDa or less than 600 KDa.

3 . The system of claim 1 , wherein the at least one hyaluronic acid is at a concentration of approximately 1.5% to approximately 2.5%.

4 . The system of claim 1 , wherein the at least one hyaluronic acid comprises a hyaluronic acid of approximately 1400 KDa to approximately 1600 KDa.

5 . The system of claim 1 , wherein the at least one hyaluronic acid comprises:

at least one low molecular weight hyaluronic acid that is approximately 600 KDa or less than 600 KDa; and

at least one high molecular weight hyaluronic acid that is approximately 4000 KDa or above 4000 KDa.

6 . The system of claim 5 wherein:

a ratio of the low molecular weight hyaluronic acid to the high molecular weight hyaluronic acid is approximately 2:3 and a total concentration of hyaluronic acid is approximately 2.2% to approximately 2.8%; or

the ratio of the low molecular weight hyaluronic acid to the high molecular weight hyaluronic acid is approximately 8:5 and the total concentration of hyaluronic acid is approximately 3% to approximately 3.5%.

7 . The system of claim 1 , wherein the anticoagulant comprises a sodium citrate.

8 . The system of claim 1 , further comprising a syringe for administering the cell composition to a patient.

9 . The system of claim 1 , the cell composition further comprising at least one of:

a coagulation activator, a thrombin serum, a tricalcium phosphate, a bone substitute, a calcium gluconate, a calcium saccharate, a chitosan, a fibroin, a silk-fibroin protein, a growth factor, a mannitol, a collagen, an albumin, an ascorbic acid, a cream, a fat cell, a fat tissue, a bone marrow concentrate, a lubricin, a cd-gelatin, a botulinum toxin, a cell extract.

10 . The system of claim 1 , the cell composition further comprising at least one of:

an analgesic compound, an antibacterial compound, an antibiotic, an antifungal compound, an anti-inflammatory, an antiparasitic compound, an antiviral compound, an enzyme, an enzyme inhibitor, a glycoprotein, a growth factor, a hormone, a steroid, a glucocorticosteroid, an immunomodulator, an immunoglobulin, a mineral, a neuroleptic, a protein, a peptide, a lipoprotein, a tumoricidal compound, a tumorstatic compound, a toxin, a vitamin.

11 . The system of claim 1 , wherein the at least one hyaluronic acid is reticulated.

12 . A system for preparing a cell composition, comprising:

a container having:

an anticoagulant and/or a cell selector gel;

at least one hyaluronic acid selected from the following:

a hyaluronic acid of approximately 1000 KDa to approximately 2000 KDa at a concentration of approximately 1.5% to approximately 2.5%;

a hyaluronic acid of approximately 4000 KDa or above 4000 KDa at a concentration of approximately 1.5% to approximately 2.5%;

a hyaluronic acid of approximately 600 KDa or less than 600 KDa.

13 . The system of claim 12 , wherein the container has a cell selector gel including a polymer, the cell selector gel adapted to separate a blood by forming a barrier between a platelet rich plasma and red blood cells when centrifuged for a length of time.

14 . The system of claim 12 , wherein the at least one hyaluronic acid is selected from the following:

a hyaluronic acid of approximately 1000 KDa to approximately 2000 KDa at a concentration of approximately 1.5% to approximately 2.5%;

a hyaluronic acid of approximately 600 KDa or less than 600 KDa.

15 . The system of claim 12 , wherein the at least one hyaluronic acid comprises at least one of the following:

a hyaluronic acid of approximately 1550 KDa at a concentration of approximately 1.8% to approximately 2.2%;

a hyaluronic acid of approximately 1550 KDa at a concentration of approximately 1.7% to approximately 2%;

a hyaluronic acid of approximately 4000 KDa at a concentration of approximately 2%;

a hyaluronic acid of approximately 4000 KDa to approximately 6000 KDa at a concentration of approximately 1.8% to approximately 2.2%.

16 . The system of claim 12 , wherein the at least one hyaluronic acid comprises:

a low molecular weight hyaluronic acid and a high molecular weight hyaluronic acid;

wherein a ratio of the low molecular weight hyaluronic acid to the high molecular weight hyaluronic acid is approximately 2:3 and a total concentration of hyaluronic acid is approximately 2.2% to approximately 2.8%; or

the ratio of the low molecular weight hyaluronic acid to the high molecular weight hyaluronic acid is approximately 8:5 and the total concentration of hyaluronic acid is approximately 3% to approximately 3.5%.

17 . The system of claim 12 , wherein the at least one hyaluronic acid is steam sterilized in the container.

18 . A method of treating a patient using a system having:

a tube;

an anticoagulant disposed in the tube;

at least one hyaluronic acid disposed in the tube, the at least one hyaluronic acid selected from the following:

a hyaluronic acid of approximately 1000 KDa to approximately 2000 KDa;

a hyaluronic acid of approximately 4000 KDa or above 4000 KDa;

a hyaluronic acid of approximately 600 KDa or less than 600 KDa;

the method comprising:

withdrawing blood from a patient;

centrifuging the blood in the tube to form a platelet rich plasma;

mixing the platelet rich plasma with the at least one hyaluronic acid to form a cell composition in the tube;

administering a therapeutically effective amount of the cell composition to tissue in the patient to promote tissue regeneration.

19 . The method of claim 18 , wherein said composition is administered as an anti-aging agent, a skin repairing agent, a scar repairing agent, a lipoatrophy repairing agent, a wrinkle filling and/or repairing agent, an aesthetic preparation, a volume corrector, and/or a hair stimulator.